Glucagon-Like Peptide-1 (GLP) for Endo/Metabolic: 77.8% of denials overturned
In 9 California IMR decisions from 2026 to 2026, reviewers overturned 7 (77.8%). In the last five years: 77.8% of 9. 9 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2026 | 9 | 77.8% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 3 | 100.0% | 77.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested reimbursement and prospective authorization and coverage for Zepbound. Zepbound is FDA‑approved for chronic weight management in patients with obesity or overweight with a related comorbidity, and it also carries an indication for moderate‑to‑severe obstructive sleep apnea in patients with obesity. Clinical guidelines recommend lifestyle modification as first‑line therapy, with weight‑loss medication …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Wegovy. Pharmacotherapy is recommended in patients with a body mass index (BMI) higher than 30 kg/m2, or 27 kg/m2 if weight-related comorbidities are present. Wegovy has proven effective for the treatment of obesity with comorbidities, including metabolic dysfunction-associated steatotic liver disease (MASLD). …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Ozempic. Published retrospective studies in patients with type 1 diabetes receiving insulin therapy have demonstrated that adjunctive semaglutide treatment may improve time in range, reduce hemoglobin A1c levels, decrease total daily insulin requirements, and promote weight loss without significantly increasing the risk …”
And one the reviewer upheld
“The physician reviewer found that a patient has requested authorization and coverage for Ozempic. Ozempic (semaglutide) is FDA‑approved for the management of blood glucose in patients with type 2 diabetes, and supporting clinical studies evaluated adults with this diagnosis. In this case, the patient received Ozempic based on a diagnosis of type 2 diabetes; however, the medical records do not …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Glucagon-Like Peptide-1 (GLP) denials for Endo/Metabolic overturned?
In 9 California IMR decisions from 2026 to 2026, reviewers overturned 7 (77.8%). In the last five years: 77.8% of 9. 9 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.